Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

PHASE3RecruitingINTERVENTIONAL

Enrollment

1,455

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

January 2, 2027

Conditions

Venous ThromboembolismAnticoagulantElderly

Interventions

DRUG

Sulodexide

2 soft capsules of Vessel® 250 LSU BID for 12 months

DRUG

Sulodexide and placebo

1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months

DRUG

Placebo

Sugar pill manufactured to mimic sulodexide 250 LSU

Trial Locations (1)

RECRUITING

Corrado Lodigiani, Rozzano

All Listed Sponsors

lead

Arianna Anticoagulazione Foundation

OTHER

NCT04257487 - Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) | Biotech Hunter | Biotech Hunter